Wealthcare Advisory Partners’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-947
Closed -$4K 1513
2020
Q1
$4K Hold
947
﹤0.01% 1199
2019
Q4
$3K Buy
+947
New +$2.46K ﹤0.01% 1230

Other funds holding BMY.RT

Wealthcare Advisory Partners's BMY.RT Position: Q2 2020 in Review

Wealthcare Advisory Partners sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q2 2020, closing a stake of 947 shares — an estimated $4K sold.

Wealthcare Advisory Partners first reported a position in BMY.RT in Q4 2019 and held it in 2 quarters. The position peaked at $4K in Q1 2020. 583 funds tracked by Wall St. Rank hold BMY.RT as of Q2 2020.

  • Wealthcare Advisory Partners reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q2 2020 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 947 Bristol-Myers Squibb Company Contingent Value Rights shares in Q2 2020, an estimated $4K.
  • Wealthcare Advisory Partners first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 2 quarters.
  • Wealthcare Advisory Partners's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $4K in Q1 2020.
  • 583 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q2 2020.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2020, filed 29 Jul 2020.